CAPR Capricor Therapeutics Inc
Company Analysis
Latest News
🟢 Capricor Therapeutics is trading 5% up today with no clear company-specific catalyst
Capricor Therapeutics is trading at $9.36 (+5.17%) with no clear company-specific catalyst identified for the September 22, 2026 gain. - Recent coverage...
Capricor Therapeutics Sued Over Deramiocel Risks, Following 64% Stock Crash
Law firms are urging investors to join a securities class action lawsuit against Capricor Therapeutics. The lead plaintiff filing deadline is September 28,...
🟢 Capricor Therapeutics is trading 12.15% up today as U.S. indexes and biotech gain
Capricor Therapeutics is trading 12.15% up at $9.60, moving alongside a broad September 17, 2026 risk-on rally. - Major U.S. indexes are higher, while biotech...
🟢 Capricor Therapeutics is trading 6.19% up today amid a broader market rebound
Capricor Therapeutics is trading 6.19% up now at $9.09, amid a broader market rebound. - The gain comes during a strong September 17, 2026, risk-on session,...
🟢 Capricor Therapeutics is trading 5% up today as Nasdaq rises
Capricor Therapeutics is trading 5% up at $9.00, apparently aligned with stronger growth-stock sentiment as the Nasdaq rises despite biotech weakness. - No...
🟢 Capricor Therapeutics is trading 6.8% up today
Capricor Therapeutics is trading at $8.94, up 6.76%, with no new company-specific announcement identified overnight explaining the September 14, 2026 move. -...
🟢 Capricor Therapeutics is trading 5% up in pre-market; no company-specific catalyst found overnight
Capricor Therapeutics is trading 5.02% up at $8.79 after closing at $8.37 on September 11, 2026; no new company-specific announcement explaining the move was...
🔴 Capricor Therapeutics is trading 5% down today amid broad market pressure from hotter producer inflation
Capricor Therapeutics is trading 5% down now at $8.21, with no new company announcement directly explaining the September 10 decline; broader markets are...
🔴 Capricor Therapeutics is trading 5.4% down today after a securities-fraud lawsuit alleges misleading Deramiocel data
Capricor Therapeutics is trading 5.43% down at $8.89 after a securities-fraud class-action lawsuit announcement on September 8, 2026. Broader markets are...
🔴 Capricor Therapeutics is trading 6.37% down today after a securities-class-action lead-plaintiff deadline announcement
Capricor Therapeutics is trading 6.37% down now at $9.26 after Robbins Geller announced a September 28, 2026 lead-plaintiff deadline for a securities class...
🟢 Capricor Therapeutics is trading 5% up today after Piper Sandler upgrade, target raised to $25
Capricor Therapeutics is trading 5.09% up now at $10.52 after Piper Sandler upgraded the shares to Overweight from Neutral and raised its price target to $25...
🟢 Capricor Therapeutics is trading 6.61% up today after Piper Sandler upgrade to Overweight
Capricor Therapeutics is trading 6.61% up now at $10.56 after Piper Sandler upgraded the stock to Overweight from Neutral and raised its price target to $25...
🟢 Capricor Therapeutics is trading 5.5% up today
Capricor Therapeutics is trading 5.53% up now at $10.12, but no new company-specific announcement clearly explains the August 31, 2026 move. - Recent...
🔴 Capricor Therapeutics is trading 5% down today after a securities-fraud class-action announcement
Capricor Therapeutics is trading at $9.55, down 5.02%, after an investor-law-firm announcement publicized a securities-fraud class action and September 28,...
🟢 Capricor Therapeutics is trading 13.03% up today after the FDA extended deramiocel’s PDUFA target date
Capricor Therapeutics is trading 13.03% up now at $10.58 after the FDA extended deramiocel’s PDUFA target date from August 22 to November 22, 2026. - The...
🟢 Capricor Therapeutics is trading 5.77% up today after FDA moves deramiocel’s PDUFA deadline
Capricor Therapeutics is trading at $9.90, up 5.77%, extending a sharp multi-session rebound after the FDA moved deramiocel’s PDUFA deadline to November 22,...
🟢 Capricor Therapeutics is trading 14.96% up today on deramiocel PDUFA deadline extension
Capricor Therapeutics is trading at $9.53 (+14.96%) after the FDA extended deramiocel’s PDUFA deadline to November 22, 2026, allowing review of new HOPE-3 data...
🟢 Capricor Therapeutics is trading 9.83% up today after FDA extended deramiocel review to November 2026
Capricor Therapeutics is trading 9.83% up at $9.11 as investors continue reacting to the FDA’s August 24 decision to extend deramiocel’s PDUFA deadline to...
🟢 Capricor Therapeutics is trading 21.62% up today after FDA extended deramiocel's decision deadline
Capricor Therapeutics is trading 21.62% up now at $8.27 after the FDA extended deramiocel’s decision deadline to November 22, 2026. - The three-month reprieve...
Capricor's Duchenne Therapy Gets a Three-Month FDA Reprieve — But Can Extra Data Overcome a Brutal Advisory Vote?
Shares of Capricor Therapeutics (CAPR) surged as much as 29% Monday before settling at $7.40 (+8.9%) after the company disclosed that the FDA pushed its...